RecruitingMajor Depressive Disorder
Optimizing Brain Excitability in Depression
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).
Sponsor: Stanford University
You may qualify if…
- ✓ Men and women, ages 18 to 65
- ✓ Diagnosis of major depressive disorder, assessed through a Structured Clinical Interview for DSM-5 (SCID-5)
- ✓ In a current depressive episode, assessed through a Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (SCID-5)
- ✓ Moderate-to-severe depression as indicated by a score between 11-20 on the Quick Inventory of Depressive Symptoms (QIDS)
- ✓ Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales
- ✓ No current or history of neurological disorders
- ✓ No seizure disorder or risk of seizures
- ✓ Neurosurgical patients: Men and women ages 18-65 with medication-refractory epilepsy who are admitted for phase II intracranial monitoring to detect a seizure focus will be considered appropriate for this study. Participants must have the intellectual capacity to understand the consent process and agree to the study.
You may not qualify if…
- ✕ Those with a contraindication for MRIs (e.g. implanted metal)
- ✕ History of head trauma with loss of consciousness
- ✕ History of seizures or on medications that reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium)
- ✕ Neurological or uncontrolled medical disease
- ✕ Any unstable medical condition
- ✕ Active substance abuse
- ✕ Diagnosis of psychotic or bipolar disorder
- ✕ A prior history of Electroconvulsive Therapy (ECT) failure
Where it's recruiting
California
Iowa City · Stanford
Source: ClinicalTrials.gov · NCT07242105 · last updated 2026-02-10